Synthetic biology has been game-changing and with generative artificial intelligence, generative biology holds immense potential; let’s just speed it up.
Category: bioengineering – Page 26
Episode Disclaimer — The views presented in this episode are those of the speaker and do not necessarily represent the views of the United States Department of Defense (DoD) or its components.
Dr. Diane DiEuliis, Ph.D. is a Distinguished Research Fellow at National Defense University (NDU — https://www.ndu.edu/), an institution of higher education, funded by the United States Department of Defense, aimed at facilitating high-level education, training, and professional development of national security leaders. Her research areas focus on emerging biological technologies, biodefense, and preparedness for biothreats. Specific topic areas under this broad research portfolio include dual-use life sciences research, synthetic biology, the U.S. bioeconomy, disaster recovery, and behavioral, cognitive, and social science as it relates to important aspects of deterrence. Dr. DiEuliis currently has several research grants in progress, and teaches in foundational professional military education.
Prior to joining NDU, Dr. DiEuliis was Deputy Director for Policy, and served as Deputy Assistant Secretary for Policy and Planning in the Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services. She coordinated policy and research in support of domestic and international health emergencies, such as Hurricane Sandy, and Ebola outbreaks. She was responsible for implementation of the Pandemic All-Hazards Preparedness Act, the National Health Security Strategy, and supported the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).
From to 2007 to 2011, Dr. DiEuliis was the Assistant Director for Life Sciences and Behavioral and Social Sciences in the Office of Science and Technology Policy (OSTP) in the Executive Office of the President. During her tenure at the White House, she was responsible for developing policy in areas such as biosecurity and biodefense, synthetic biology, social and behavioral science, scientific collections, and biotechnology. Dr. DiEuliis also worked to help coordinate agency response to public health issues such as the H1N1 flu.
Prior to working at OSTP, Dr. DiEuliis was a program director at the National Institutes of Health (NIH), where she managed a diverse portfolio of neuroscience research in neurodegenerative diseases. She completed a fellowship at the University of Pennsylvania in the Center for Neurodegenerative Disease Research and completed her postdoctoral research in the NIH Intramural research program, where she focused on cellular and molecular neuroscience.
Dr. DiEuliis is a National Merit Scholar, and has a Ph.D. in biology from the University of Delaware in Newark, Delaware. She is the author of over 70 publications.
This video explores the 4th to the 10th dimensions of time. Watch this next video about the 10 stages of AI: • The 10 Stages of Artificial Intelligence.
5 Free ChatGPT Prompts To Become a Superhuman: https://bit.ly/3Oka9FM
AI for Business Leaders (Udacity Program): https://bit.ly/3Qjxkmu.
My Patreon: / futurebusinesstech.
Official Discord Server: / discord.
Future Business Tech explores the future of technology and the world.
Examples of topics I cover include:
• Artificial Intelligence \& Robotics.
• Virtual and Augmented Reality.
• Brain-Computer Interfaces.
• Transhumanism.
• Genetic Engineering.
SUBSCRIBE: https://bit.ly/3geLDGO
Disclaimer:
Some links in this description are affiliate links.
As an Amazon Associate, I earn from qualifying purchases.
This video explores the 4th to the 10th dimensions of time. Other related terms: advanced civilization, ai, artificial intelligence, future business tech, future technology, future tech, future business technologies, future technologies, aliens, higher dimensions, 10th dimension, 4th dimension, 5th dimension, 6th dimension, 7th dimension, 8th dimension, 9th dimension, time travel, etc.
ESA’s newly graduated astronauts reach the end of one year of rigorous basic astronaut training. Discover the journey of Sophie Adenot, Rosemary Coogan, Pablo Álvarez Fernández, Raphaël Liégeois, Marco Sieber, and Australian Space Agency astronaut candidate Katherine Bennell-Pegg. Selected in November 2022, the group began their training in April 2023.
Basic astronaut training provides the candidates with an overall familiarisation and training in various areas, such as spacecraft systems, spacewalks, flight engineering, robotics and life support systems as well as survival and medical training. They received astronaut certification at ESA’s European Astronaut Centre on 22 April 2024.
Following certification, the new astronauts will move on to the next phases of pre-assignment and mission-specific training — paving the way for future missions to the International Space Station and beyond.
Credits:
Video: ESA — European Space Agency.
ISS and EVA footage: ESA/NASA
Music: Scorekeepers.
★ Subscribe: http://bit.ly/ESAsubscribe and click twice on the bell button to receive our notifications.
Researchers at the Francis Crick Institute, the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) and Aalborg University in Denmark have found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer.
Reported today in Science, the researchers found that mice given a diet rich in vitamin D had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment. This effect was also seen when gene editing was used to remove a protein that binds to vitamin D in the blood and keeps it away from tissues.
Surprisingly, the team found that vitamin D acts on epithelial cells in the intestine, which in turn increase the amount of a bacteria called Bacteroides fragilis. This microbe gave mice better immunity to cancer as the transplanted tumours didn’t grow as much, but the researchers are not yet sure how.
Structural and dynamic DNA nanosciences offer unique tools for engineering bottom–up synthetic cells. This Review provides a holistic overview for using DNA as a structural material, for designing functional entities, and for information-processing circuits for adaptive and interactive behaviour.
A trailblazer in the field of therapeutic genome editing, Fyodor D. Urnov’s research focuses on developing medicines for devastating genetic diseases.
Jason Comander, MD, PhD, performs the procedure to deliver the CRISPR-based medicine as part of the BRILLIANCE trial in September 2020 at Mass Eye and Ear. Credit: Mass Eye and Ear.
All 14 trial participants, including 12 adults (ages 17 to 63) and two children (ages 10 and 14), were born with a form of Leber Congenital Amaurosis (LCA) caused by mutations in the centrosomal protein 290 (CEP290) gene. They underwent a single injection of a CRISPR/Cas9 genome editing medicine, EDIT-101 in one eye via a specialized surgical procedure. This trial, which included the first patient to ever receive a CRISPR-based investigational medicine directly inside the body, focused primarily on safety with a secondary analysis for efficacy.
No serious treatment or procedure-related adverse events were reported, nor were there any dose-limiting toxicities. For efficacy, the researchers looked at four measures: best-corrected visual acuity (BCVA); dark-adapted full-field stimulus testing (FST), visual function navigation (VNC, as measured by a maze participants completed), and vision-related quality of life.
A simple and robust strategy developed by KAUST scientists could help to improve the safety and accuracy of CRISPR gene editing, a tool that is already approved for clinical use for the treatment of inherited blood disorders.
Following the landmark approval of the first CRISPR-based cell therapy in December 2023, the CRISPR community is looking ahead to the next wave of commercial successes, fueled by continued innovation in the development of new gene editing and delivery tools and technologies. Equally exciting advances are occurring in livestock editing, xenotransplantation, and many other specialties.
In The State of CRISPR and Gene Editing virtual summit, GEN proudly gathers a tantalizing line-up of luminaries from academia and industry to discuss the latest research developments, innovations, and advanced technologies that are expanding the CRISPR toolbox, delivering new therapies to patients and safeguarding our food supply.